Share

February 07, 2017; 88 (6) Article

Dystonia treatment

Patterns of medication use in an international cohort

Sarah Pirio Richardson, Ashley R. Wegele, Betty Skipper, Amanda Deligtisch, H.A. Jinnah, For the Dystonia Coalition Investigators
First published January 11, 2017, DOI: https://doi.org/10.1212/WNL.0000000000003596
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
472

Share

Article Information

vol. 88 no. 6 543-550
DOI: 
https://doi.org/10.1212/WNL.0000000000003596
PubMed: 
28077492
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received July 12, 2016
  • Accepted in final form November 8, 2016
  • First Published January 11, 2017.

Article Versions

Copyright & Usage: 
© 2017 American Academy of Neurology

Author Disclosures

    1. Sarah Pirio Richardson, MD,
    2. Ashley R. Wegele, BS,
    3. Betty Skipper, PhD,
    4. Amanda Deligtisch, MD,
    5. H.A. Jinnah, MD, PhD;
    6. For the Dystonia Coalition Investigators
  1. Sarah Pirio Richardson, MD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. National Center for Research Resources and National Center for Advancing Translational Sciences of the National Institutes of Health, KL2 1TR001448-01 and Grant Number UL1 TR000041, Role KL2 scholar

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Ashley R. Wegele, BS,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Betty Skipper, PhD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) NIH/NHLBI, R01HL118734, Biostatistician, 2013-2018 (2) NIH/NIMH, 1R34MH097834-01A1, Biostatistician, 2013- 2016 (3) NIH/NCRR, 1ULRR031977-01, Biostatistician, 2010-2015 (4) NIH/National Center on Minority Health and Disparities, Biostatistician, 2010-2015

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Family Services of San Francisco

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Amanda Deligtisch, MD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. H.A. Jinnah, MD, PhD;
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Dystonia Medical Research Foundation, (2) Movement Disorders Society

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Medtronic, Inc. (2) Saol Therapeutics, Inc. (3) Retrophin, Inc.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical procedures or imaging studies:

    1. Botulinum toxin injections as a clinical service

    Research Support, Commercial Entities:

    1. (1) Medtronic, Inc. (2) Merz Pharmaceuticals (3) IPSEN Pharmaceuticals

    Research Support, Government Entities:

    1. PI: NINDS NS065701, TR001456

    Research Support, Academic Entities:

    1. (1) Emory Neurosciences Initiative (2) Atlanta Clinical and Translational Institute (3) Emory University Research Council

    Research Support, Foundations and Societies:

    1. (1) Dystonia Medical Research Foundation (3) Lesch-Nyhan Syndrome Children's Research Foundation (4) Cure Dystonia Now (5) Dystonia Coalition (6) Benign Essential Blepharospasm Research Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. For the Dystonia Coalition Investigators
    1. From the Departments of Neurology (S.P.R., A.R.W., A.D.) and Family and Community Medicine (B.S.), University of New Mexico Health Sciences Center, Albuquerque; and Departments of Neurology, Human Genetics, and Pediatrics (H.A.J.), Emory University School of Medicine, Atlanta, GA.
    1. Correspondence to Dr. Pirio Richardson: spiriorichardson{at}salud.unm.edu
    View Full Text

    Article usage

    Article usage: January 2017 to April 2023

    AbstractFullPdfSource
    Jan 20171134153Highwire
    Feb 201724364187Highwire
    Mar 20174851322Highwire
    Apr 2017208114Highwire
    May 20171761410Highwire
    Jun 2017173512Highwire
    Jul 20177685Highwire
    Aug 20176645Highwire
    Sep 201710536Highwire
    Oct 201778410Highwire
    Nov 20178334Highwire
    Dec 20179503Highwire
    Jan 20187917Highwire
    Feb 201810455Highwire
    Mar 20187224Highwire
    Apr 20184964Highwire
    Apr 2018113029pmc
    May 20186926Highwire
    Jun 20185832Highwire
    Jun 2018103637pmc
    Jul 20186604Highwire
    Aug 20184921Highwire
    Aug 201874040pmc
    Sep 20187039Highwire
    Oct 20186534Highwire
    Nov 20187032Highwire
    Dec 20185300Highwire
    Jan 20196946Highwire
    Feb 20195112Highwire
    Mar 20197412Highwire
    Apr 20195253Highwire
    May 20195044Highwire
    Jun 20194210Highwire
    Jul 20193800Highwire
    Aug 20192904Highwire
    Sep 20193465Highwire
    Oct 20193802Highwire
    Nov 20194356Highwire
    Dec 20191710Highwire
    Jan 20202562Highwire
    Feb 20203442Highwire
    Mar 20205100Highwire
    Apr 20202912Highwire
    May 20202512Highwire
    Jun 20202731Highwire
    Jul 20205010Highwire
    Aug 202015321Highwire
    Sep 20205621Highwire
    Oct 20204220Highwire
    Nov 20204431Highwire
    Dec 20204855Highwire
    Jan 20216412Highwire
    Feb 20212820Highwire
    Mar 20216153Highwire
    Apr 20216501Highwire
    May 20216000Highwire
    Jun 20215331Highwire
    Jul 20215821Highwire
    Aug 20215882Highwire
    Sep 20214355Highwire
    Oct 20217415Highwire
    Nov 202110711Highwire
    Dec 20215433Highwire
    Jan 20224213Highwire
    Feb 20224403Highwire
    Mar 20225044Highwire
    Apr 20225711Highwire
    May 20228510Highwire
    Jun 20223000Highwire
    Jul 20223823Highwire
    Aug 20223621Highwire
    Sep 20224621Highwire
    Oct 20223400Highwire
    Nov 20227921Highwire
    Dec 20226251Highwire
    Jan 20235500Highwire
    Feb 20234211Highwire
    Mar 20234000Highwire
    Apr 20234843Highwire

    Cited By...

    Letters: Rapid online correspondence

    No comments have been published for this article.
    Comment

    REQUIREMENTS

    You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

    Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

    If you are responding to a comment that was written about an article you originally authored:
    You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
    and apply to letter.

    Submission specifications:

    • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
    • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
    • Submit only on articles published within 6 months of issue date.
    • Do not be redundant. Read any comments already posted on the article prior to submission.
    • Submitted comments are subject to editing and editor review prior to posting.

    More guidelines and information on Disputes & Debates

    Compose Comment

    More information about text formats

    Plain text

    • No HTML tags allowed.
    • Web page addresses and e-mail addresses turn into links automatically.
    • Lines and paragraphs break automatically.
    Author Information
    NOTE: The first author must also be the corresponding author of the comment.
    First or given name, e.g. 'Peter'.
    Your last, or family, name, e.g. 'MacMoody'.
    Your email address, e.g. higgs-boson@gmail.com
    Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
    Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
    Publishing Agreement
    NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

    Vertical Tabs

    You May Also be Interested in

    Back to top
    Advertisement

    Topics Discussed

    Alert Me

    Recommended articles